Information regarding the efficacy of the angiotensin II receptor blocker telmisartan for the treatment of proteinuria in dogs is limited.The objective of this prospective, randomized, double-masked clinical trial was to evaluate the antiproteinuric efficacy of orally administered telmisartan in dogs with persistent, pathologic, renal proteinuria, when compared to enalapril. Client-owned dogs with chronic kidney disease and urinary protein-to-creatinine ratio (UPC) >1.0 (if non-azotemic) or >0.5 (if azotemic) were eligible for enrollment.
展开▼
